On January 27, 2023, the U.S. Food and Drug Administration approved Pirtobrutinib for adult patients with histologically confirmed relapsed or refractory Mantle cell lymphoma intolerant to two or more standard therapies, one
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary refractory Large b-cell lymphoma who were candidates
More
On January 27, 2023, the U.S. Food and Drug Administration approved Pirtobrutinib for adult patients with histologically confirmed relapsed or refractory Mantle cell lymphoma intolerant to two or more standard therapies, one
More